Compare BLLN & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLLN | LAZ |
|---|---|---|
| Founded | 2016 | 1848 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.4B |
| IPO Year | 2025 | 2004 |
| Metric | BLLN | LAZ |
|---|---|---|
| Price | $104.82 | $36.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $126.71 | $52.75 |
| AVG Volume (30 Days) | 501.7K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.21% |
| EPS Growth | ★ 103.40 | N/A |
| EPS | 0.48 | ★ 0.91 |
| Revenue | $305,112,000.00 | ★ $3,186,466,000.00 |
| Revenue This Year | $46.29 | $13.36 |
| Revenue Next Year | $30.14 | $13.72 |
| P/E Ratio | $220.69 | ★ $39.26 |
| Revenue Growth | ★ 99.97 | 1.48 |
| 52 Week Low | $61.96 | $35.16 |
| 52 Week High | $150.44 | $58.75 |
| Indicator | BLLN | LAZ |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 31.71 |
| Support Level | $79.07 | N/A |
| Resistance Level | $108.50 | $45.71 |
| Average True Range (ATR) | 5.08 | 2.06 |
| MACD | 1.86 | -0.78 |
| Stochastic Oscillator | 64.44 | 12.64 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Lazard Inc is a financial advisory and asset management firm with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Geographically, the company earns key revenue in the Americas, EMEA then Asia-Pacific.